Latest news with #clinicalstudy
Associated Press
a day ago
- Business
- Associated Press
Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients
accurately predicted response in prospective cohort; results published in JCO Precision Oncology, a journal of ASCO SINGAPORE, July 28, 2025 / / -- A prospective clinical study published in JCO Precision Oncology, a journal of the American Society of Clinical Oncology (ASCO), confirms that KYAN Technologies' platform (Quadratic Phenotypic Optimization Platform, or QPOP) accurately predicts clinical response in relapsed/refractory non-Hodgkin lymphoma (R/R-NHL), including hard-to-treat subtypes where genomic testing often offers limited guidance. This prospective clinical validation study, conducted in 117 patients across two tertiary cancer centers, represents the largest published cohort to date using an ex vivo functional precision medicine platform in lymphoma. The results demonstrated meaningful clinical utility, reporting both objective response rates (ORR) and Kaplan-Meier survival outcomes, with significantly longer progression-free survival (PFS) in patients treated with combinations prioritized by the platform. The study showed that functionally guided therapies delivered not just predictive concordance, but measurable clinical benefit in a real-world setting. Key study findings: • 74.5 percent test accuracy in predicting clinical response • 59 percent ORR in patients treated with platform-guided combinations • Three-fold improvement in PFS compared to prior treatment line • Two-year survival analysis showed a statistically significant benefit over salvage therapy (P = 0.0191) 'This study reinforces the scientific rigor behind the platform by showing we can deliver reproducible, clinically concordant results across a large cohort of real patient samples,' said Edward K. Chow, PhD, KYAN Technologies' Chief Scientific Officer. 'We're especially grateful to the essential contributions of our clinical collaborators at the National University of Singapore (NUS), National University Hospital (NUH), and Singapore General Hospital (SGH). Their guidance, insights and commitment helped shape a platform that delivers timely, reliable, and actionable guidance for both physicians and patients.' directly measures how live tumor cells respond to therapy. Using a proprietary experimental design, the platform tests hundreds of clinically relevant drug treatments at once, including standard-of-care regimens, off-label therapies with known safety profiles, and novel options, and ranks them based on predicted treatment response. This functional, patient-specific readout provides oncologists with real-time guidance tailored to the biology of each tumor. 'This study marks a defining milestone in journey toward clinical adoption. With our clinical and analytical validation now published in a peer-reviewed journal, we're positioned to scale the platform in the U.S., starting with CLIA deployment and expanding through partnerships with leading clinicians and institutions,' said Hugo Saavedra, Chief Executive Officer of KYAN Technologies. The results underscore the broader potential of functional precision medicine to inform treatment decisions and combination design across oncology. By capturing how each patient's tumor responds to a breadth of drug regimens, not only guides clinical care but also offers insights that can support off-label strategy, clinical trial selection, and future drug development. About KYAN Technologies KYAN Technologies is a functional precision oncology company accelerating the discovery and deployment of effective cancer treatments. Its proprietary platform, uses ex vivo testing and combinatorial analytics to generate phenotypic response data from patient-derived tumor samples. This approach provides a clinically actionable layer of insight that complements genomic and transcriptomic tools. supports both patient care and drug development, helping clinicians identify tailored treatment options and enabling biopharma partners to prioritize combination strategies, select indications, and design smarter trials. Headquartered in Singapore, KYAN is expanding its U.S. presence to advance clinical deployment and strategic collaborations across oncology research and care. For media inquiries contact: Sudha Sruthi, Corporate Development email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
2 days ago
- Business
- Yahoo
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the . Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target. A healthcare professional discussing treatment options for a patient with a neurological disorder. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders. Operating from its headquarters in California, the company gained U.S. approval for valbenazine (Ingrezza®) for tardive dyskinesia and markets treatments for Huntington's chorea, adrenal hyperplasia, endometriosis, and uterine fibroids. The company's comprehensive pipeline includes treatments for Parkinson's, Tourette's, and novel agents like NBI‑1117568 in schizophrenia trials. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the termination of its Phase 2 study on NBI-921352, an investigational drug, as of July 14, 2025. The company, with its tests, aimed to evaluate the safety and tolerability of the drug when used alongside other treatments for patients with SCN8A-DEE, a rare and severe neurological disorder. Phase 2 of the study involved assessing the drug's ability to reduce seizure frequency in patients with SCN8A-DEE. As it failed to show a meaningful reduction, the study was terminated. The company's lead candidates continue to be crinecerfont for congenital adrenal hyperplasia (CAH), and NBI-1117568, a potential treatment for psychosis and cognitive disorders. Later, on July 21, 2025, Truist initiated coverage of the stock with a Buy rating and a price target of $163. On the other hand, Morgan Stanley, while maintaining the Buy rating, has raised the price target from $148 to $150. Despite the trial setback, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) continues to show strong growth prospects with a 33.73% projected EPS increase and a low beta of 0.25. While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Sign in to access your portfolio
Globe and Mail
2 days ago
- Business
- Globe and Mail
Bayer AG's Exploratory Study on Sepsis and DIC: A Potential Game-Changer?
Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bayer AG is conducting an exploratory study titled 'Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis.' The study aims to understand how sepsis progresses to DIC, a severe blood disorder, by identifying biomarkers in patients admitted to intensive care units across Europe. This research is significant due to the limited treatment options for DIC, especially in sepsis patients. The study involves no investigational treatments; instead, participants receive standard medical care for sepsis. The focus is on collecting blood samples and clinical data to identify biomarkers indicative of DIC development. Designed as an interventional study with a single-group model, this research does not involve masking and primarily seeks to gather observational data. The study's primary purpose is to explore the progression of sepsis to DIC. The study began on January 29, 2025, with primary completion expected within 56 days for each participant. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and data collection. This study could impact Bayer's stock performance by potentially enhancing its reputation in the medical research field, especially if the findings lead to improved understanding and treatment of sepsis-related DIC. Investors may view this as a positive development, although the absence of new drug interventions limits immediate commercial implications. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
2 days ago
- Business
- Globe and Mail
AstraZeneca's AZD4144 Study Completion: Key Insights for Investors
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, recently completed a Phase I clinical study titled An Open-label, Randomised, 2-arm, 3-period, 6-treatment Single-dose, Crossover Study Comparing the Pharmacokinetics of 2 Different Formulations of AZD4144, and Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants. The study aimed to evaluate the pharmacokinetics of two formulations of AZD4144 and the impact of food and omeprazole on its absorption in healthy individuals. The study tested two formulations of AZD4144, an investigational drug, in tablet and oral solution forms. It also assessed the effect of omeprazole, a commonly used medication for reducing stomach acid, on AZD4144's pharmacokinetics. This open-label, randomized, crossover study involved two arms with different treatment sequences. Participants received single doses of AZD4144 under various conditions, including fasted and fed states, and in combination with omeprazole. The primary goal was to understand how these factors influence the drug's absorption and processing in the body. The study commenced on April 23, 2025, and was completed by July 22, 2025. These dates are crucial as they mark the timeline of the study's execution and data collection, which can affect the timing of subsequent phases and regulatory submissions. This update could influence AstraZeneca's stock performance by providing insights into the drug's development progress. Positive results might boost investor confidence, while any setbacks could have the opposite effect. The study's completion also positions AstraZeneca competitively within the pharmaceutical industry as it advances its pipeline. The study is now completed, with further details available on the ClinicalTrials portal.
Globe and Mail
2 days ago
- Business
- Globe and Mail
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.
